Spoken Alpha
Apyx Medical Corp
Apyx Medical designs and manufactures surgical aesthetic devices using Helium Plasma Technology, marketed as Renuvion for cosmetic surgery and J-Plasma for hospital surgical markets, along with the AYON body contouring system that combines fat removal, tissue contouring, and skin tightening capabilities.
Apyx Medical Corp is a Healthcare company operating in Medical Devices with a $126.8M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for APYX.
$ curl https://api.spokenalpha.com/v1/companies/APYXFAQ
Spoken Alpha indexes APYX's earnings call transcripts at https://spokenalpha.com/companies/APYX. Each call links to attributed speakers and parsed analyst Q&A.
Apyx Medical Corp (APYX) held its most recent earnings call on 2026-08-06, covering fiscal Q2 2026.
Apyx Medical Corp (APYX) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-0.07 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.07 | $-0.06 | -16.7% | $13.9M | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.05 | $-0.11 | +54.5% | $12.5M | — | — | EODHD |
| Q4 FY2025 | 2026-03-09 | $-0.03 | $-0.06 | +46.4% | $19.2M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.05 | $-0.10 | +50.0% | $12.9M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.09 | $-0.09 | 0.0% | $11.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.10 | $-0.12 | +16.7% | $9.4M | — | — | EODHD |
| Q4 FY2024 | 2025-03-12 | $-0.12 | $-0.16 | +25.0% | $14.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-07 | $-0.14 | $-0.19 | +26.3% | $11.5M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.19 | $-0.19 | 0.0% | $12.1M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.22 | $-0.19 | -15.8% | $10.2M | — | — | EODHD |
| Q4 FY2023 | 2024-03-20 | $-0.28 | $-0.18 | -55.6% | $14.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.13 | $-0.11 | -18.2% | $12.0M | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.11 | $-0.09 | -22.2% | $13.6M | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.10 | $-0.14 | +28.6% | $12.1M | — | — | EODHD |
| Q4 FY2022 | 2023-03-15 | $-0.17 | $-0.14 | -21.4% | $12.6M | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.17 | $-0.14 | -21.4% | $9.1M | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.16 | $-0.19 | +15.8% | $10.3M | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.17 | $-0.15 | -13.3% | $12.5M | — | — | EODHD |
| Q4 FY2021 | 2022-03-16 | $-0.06 | $-0.11 | +45.5% | $16.8M | — | — | EODHD |
Source: EODHD. APYX reported actuals as published; sparse fields render as —.